Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients

Last updated: September 23, 2019
Sponsor: Seoul National University Hospital
Overall Status: Completed

Phase

4

Condition

Liver Transplantation

Dementia

Treatment

N/A

Clinical Study ID

NCT02245256
1407-114-596
  • Ages 18-100
  • All Genders

Study Summary

To test the effect of low-dose dexmedetomidine for lowering the incidence of postoperative delirium in liver transplant patients in the ICU.

Single center prospective randomized placebo controlled clinical trial 0.1mcg/kg/hr of dexmedetomidine or equivalent amount of saline infusion started after induction of anesthesia for liver transplantation and continued until 48 hours after surgery.

Outcomes will be assessed up to 1 week or transfer to ward, whichever comes first.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adult patients (18years old or older) undergoing living-donor or deceased-donor livertransplantation

Exclusion

Exclusion Criteria:

  • Pediatric patients (under 18 years) Pregnancy Patients who are unresponsive atbaseline, who have neurologic deficits at baseline, or who are allergic todexmedetomidine

Study Design

Total Participants: 217
Study Start date:
September 01, 2014
Estimated Completion Date:
February 01, 2018

Connect with a study center

  • Seoul National University Hospital

    Seoul, Agree 110-744
    Korea, Republic of

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.